Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

AGP14 for COVID-19

AGP14 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
unknown, u., Identification of Potential Semisynthetic Andrographolide Derivatives to Combat COVID-19 by Targeting the SARS-COV-2 Spike Protein and Human ACE2 Receptor– An In-silico Approach, Biointerface Research in Applied Chemistry, doi:10.33263/BRIAC132.155
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal factor for the current deadly infectious disease CoVID-19. There is no specific drug available for treating COVID-19 other than some vaccines approved for prevention. However, a lot of research is in progress to prove the anti-COVID-19 potential of natural and synthetic compounds. Objective: The present study was aimed to identify the anti-COVID-19 potential of andrographolide (AGP) derivatives by in-silico molecular interaction study. Seventeen AGP derivatives were screened for drug-likeness, ADME, and toxicity profile using in-silico online tools. Then the filtered AGP were subjected to molecular docking using the PyRx tool integrated with AutoDock Vina software. Compounds AGP 15, 14, and 10 have been identified as promising binding molecules for both S and ACE2, preventing the interaction between S and ACE2. AGP-15 had shown a −8.4 Kcal/mol binding/docking score for S, AGP-10 and 14 showed a -8.3 and -8.2 Kcal/mol binding/docking score for ACE2. Overall results indicated that AGP derivatives 15 and 14 might be the best candidates to battle COVID-19. However, further studies like dynamic molecular studies and pharmacological screenings are essential to confirm the stability and action potential of AGP derivatives 14 and 15 as a lead against COVID-19.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit